From Recent Issues

What Cancer Patients May or May Not Be Surprised to Know About Survivorship

Abstract: The number of US cancer survivors has increased from fewer than 4 million in the 1970s to 18.1 million in 2022, with the increase reflecting […]

Unlocking the Potential of Patient-Reported Outcomes: Practical Uses in Routine Oncology Care

Abstract: A growing body of evidence supports the use of remote symptom monitoring based on patient-reported outcomes (PROs) to manage symptoms, improve quality of life, and […]

Converging Approaches in the Frontline Treatment of Mantle Cell Lymphoma

Abstract: Mantle cell lymphoma is a biologically and clinically heterogeneous subtype of non-Hodgkin lymphoma that affects predominantly older patients. The disease remains incurable with modern therapies. […]

Supplements

Translating FRESCO Clinical Trial Evidence Into Practice: Fruquintinib as Post–Standard Third-Line Therapy Followed by Trifluridine/Tipiracil in a Patient With mCRC Without Targetable Mutations

In the Clinic JR is a 54-year-old male who was diagnosed with left-side transverse colon adenocarcinoma metastatic to the peritoneum and liver (Table 1). A next-generation […]

Navigating the Paroxysmal Nocturnal Hemoglobinuria (PNH) Landscape

Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal hematopoietic stem cell disorder in which a somatic mutation in PIGA leads to reduced or absent expression of […]

The Promise of Molecular Residual Disease (MRD) Testing for Patients With Colorectal Cancer

Abstract: Molecular residual disease (MRD) assays using circulating tumor DNA (ctDNA) have the potential to detect colorectal cancer recurrence earlier than current standard-of-care surveillance techniques, such as […]